Avita Medical (ASX:AVH) reported Friday a loss of $0.44 per diluted share in the fourth quarter of 2024, compared with a loss of $0.28 per diluted share in the same period in 2023.
Analysts polled by Visible Alpha also expected a loss of $0.44.
The dual-listed firm said the wider net loss was due to higher operating expenses and lower other income, net, partially offset by higher gross profit.
Total revenue in the quarter ended Dec. 31, 2024, came in at $18.4 million, compared with $14.2 million in the corresponding period in the prior year. Analysts polled by Visible Alpha expected $20.3 million.
The company said it expects its full-year 2025 commercial revenue to be in the range of $100 to $106 million, reflecting growth of approximately 55% to 65% over the full-year 2024.
The company's shares surged past 12% in recent Friday trade in Australia.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。